BiomimX
BiomimX is dedicated to advancing new therapies by unlocking human-relevant data through innovative in vitro models that reflect human complexity. They develop Beating Organs-on-Chip, microphysiological systems that mimic human tissues and pathologies, to improve drug discovery, efficacy testing, and safety assessment. Their mission is to revolutionize preclinical research and bring effective, personalized treatments to patients.
Industries
Nr. of Employees
small (1-50)
BiomimX
Products
Mechanical stimulation platform for 3D cell culture
Laboratory platform that supports culture of multiple independent 3D microtissues with programmable mechanical stimulation modes (uniaxial stretch and confined compression) to reproduce organ-specific mechanical environments.
Programmable pneumatic actuator and controller
Control unit delivering pneumatic pressure to culture devices with user-selectable stimulation patterns (frequency, duty cycle, timing) enabling reproducible mechanical conditioning.
Pre-configured experimental kits and starting packages
Kit bundles including platform devices, controller hardware, user guides, training materials and customer support designed for mid-throughput experimental campaigns.
Mechanical stimulation platform for 3D cell culture
Laboratory platform that supports culture of multiple independent 3D microtissues with programmable mechanical stimulation modes (uniaxial stretch and confined compression) to reproduce organ-specific mechanical environments.
Programmable pneumatic actuator and controller
Control unit delivering pneumatic pressure to culture devices with user-selectable stimulation patterns (frequency, duty cycle, timing) enabling reproducible mechanical conditioning.
Pre-configured experimental kits and starting packages
Kit bundles including platform devices, controller hardware, user guides, training materials and customer support designed for mid-throughput experimental campaigns.
Services
Contract screening of candidate compounds for cardiac safety using beating 3D cardiac tissue models with functional electrical readouts and validated performance metrics.
Assessment of therapeutic efficacy and mode-of-action in disease-relevant mechanically active 3D models (examples include cartilage-on-chip for osteoarthritis and cardiac fibrosis models).
Toxicity and efficacy testing of gene therapies, antibody-drug conjugates and cell-based therapeutics in tailored human-relevant in vitro models.
Evaluation of gut epithelium–microbiome interactions using mechanically active intestinal models incorporating human faecal samples to study patient-specific responses.
In vitro evaluation of medical device efficacy within clinically relevant mechanically active models to inform preclinical evidence packages aligned with regulatory expectations.
Collaborative development of new organ and multi-tissue models, patient-specific models and bespoke assays; support for project scoping and co-development from discovery to lead optimization.
Contract screening of candidate compounds for cardiac safety using beating 3D cardiac tissue models with functional electrical readouts and validated performance metrics.
Assessment of therapeutic efficacy and mode-of-action in disease-relevant mechanically active 3D models (examples include cartilage-on-chip for osteoarthritis and cardiac fibrosis models).
Toxicity and efficacy testing of gene therapies, antibody-drug conjugates and cell-based therapeutics in tailored human-relevant in vitro models.
Evaluation of gut epithelium–microbiome interactions using mechanically active intestinal models incorporating human faecal samples to study patient-specific responses.
In vitro evaluation of medical device efficacy within clinically relevant mechanically active models to inform preclinical evidence packages aligned with regulatory expectations.
Collaborative development of new organ and multi-tissue models, patient-specific models and bespoke assays; support for project scoping and co-development from discovery to lead optimization.
Expertise Areas
- Organs-on-chip and microphysiological systems development
- Mechanobiology and 3D dynamic tissue engineering
- Preclinical safety pharmacology and cardiotoxicity prediction
- Preclinical efficacy testing and mechanism-of-action studies
Key Technologies
- Microfluidic organ-on-chip platforms
- Programmable mechanical stimulation (stretch/compression)
- Continuous microelectrode-based electrophysiological recording
- Force sensing for tissue mechanics
News & Updates
BiomimX was awarded third prize at the GrandPrixInnovation in November 2023.
In October 2022, BiomimX was selected for the Berkeley SkyDeck Europe acceleration program.
In March 2022, Paola Occhetta was recognized among women entrepreneurs supported by the European Union.
A publication in Nature Biomedical Engineering demonstrating the uGut model’s capabilities.
A study published in Advanced Healthcare Materials on the efficacy testing of SYN321.
A publication in Advanced Materials Technologies on the LivHeart platform.
BiomimX was awarded third prize at the GrandPrixInnovation in November 2023.
In October 2022, BiomimX was selected for the Berkeley SkyDeck Europe acceleration program.
In March 2022, Paola Occhetta was recognized among women entrepreneurs supported by the European Union.
A publication in Nature Biomedical Engineering demonstrating the uGut model’s capabilities.
A study published in Advanced Healthcare Materials on the efficacy testing of SYN321.
A publication in Advanced Materials Technologies on the LivHeart platform.